Literature DB >> 7378254

Pharmacokinetics of atenolol in patients with terminal renal failure and influence of haemodialysis.

B Flouvat, S Decourt, P Aubert, L Potaux, M Domart, A Goupil, A Baglin.   

Abstract

1 The pharmacokinetics of atenolol, after 200 mg orally, were studied in 18 patients with terminal renal insufficiency (creatinine clearance less than 5 ml/min), of whom twelve were being treated by chronic dialysis. 2 The peak plasma level, 1.59 +/- 0.43 mg/l, was reached in 4.7 +/- 2.1 h. 3 Without dialysis treatment, the apparent plasma half-life of atenolol was greatly increased (73.4 +/- 28.8 /). During dialysis, it dropped to 7.5 +/- 3.7 h but returned to 51.2 +/- 17.3 h after dialysis. The plasma atenolol plot was a rising slope for a few hours after the end of dialysis. 4 Renal clearance of atenolol was very low (4.6 +/- 1.5 ml/min). 5 Plasma clearance during dialysis was 42.6 +/- 21.3 ml/min for a mean blood flow-rate of 236 +/- 25 ml/min through a cuprophane membrane dialyser. 6 These results suggest that dosage should be modified for these patients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7378254      PMCID: PMC1429992          DOI: 10.1111/j.1365-2125.1980.tb01065.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  A study of practolol elimination in all grades of chronic renal failure.

Authors:  C M Kaye; C R Kumana; D A Franklin; L R Baker
Journal:  Int J Clin Pharmacol Biopharm       Date:  1975-07

2.  Influence of the hemodialysis on the half-life of practolol in patients with severe renal failure.

Authors:  C Harvengt; J P Desager; J M Muschart; Y B Tjandramaga; R Verbeeck; R Verberckmoes
Journal:  J Clin Pharmacol       Date:  1975 Aug-Sep       Impact factor: 3.126

3.  Pharmacokinetics of oral propranolol in chronic renal disease.

Authors:  D T Lowenthal; W A Briggs; T P Gibson; H Nelson; W J Cirksena
Journal:  Clin Pharmacol Ther       Date:  1974-11       Impact factor: 6.875

4.  Pharmacodynamics of practolol in chronic renal failure.

Authors:  J B Eastwood; J R Curtis; R B Smith
Journal:  Br Med J       Date:  1973-11-10

5.  Pharmacodynamics of propranolol in renal failure.

Authors:  F D Thompson; A M Joekes; D M Foulkes
Journal:  Br Med J       Date:  1972-05-20

6.  Atenolol and bendrofluazide in hypertension.

Authors:  J C Petrie; D B Galloway; J Webster; W T Simpson; J A Lewis
Journal:  Br Med J       Date:  1975-10-18

7.  A new type of cardioselective adrenoceptive blocking drug.

Authors:  A M Barrett; J Carter; J D Fitzgerald; R Hull; D Le Count
Journal:  Br J Pharmacol       Date:  1973-06       Impact factor: 8.739

8.  Controlled study of atenolol in treatment of hypertension.

Authors:  L Hansson; H Aberg; B E Karlberg; A Westerlund
Journal:  Br Med J       Date:  1975-05-17

9.  Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.

Authors:  H C Brown; S G Carruthers; G D Johnston; J G Kelly; J McAinsh; D G McDevitt; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1976-11       Impact factor: 6.875

10.  The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol.

Authors:  T B Tjandramaga; R Verbeeck; J Thomas; R Verbesselt; R Verberckmoes; P J Schepper
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

View more
  8 in total

1.  β-Blocker dialyzability and mortality in older patients receiving hemodialysis.

Authors:  Matthew A Weir; Stephanie N Dixon; Jamie L Fleet; Matthew A Roberts; Daniel G Hackam; Matthew J Oliver; Rita S Suri; Robert R Quinn; Sundus Ozair; Michael M Beyea; Abhijat Kitchlu; Amit X Garg
Journal:  J Am Soc Nephrol       Date:  2014-10-30       Impact factor: 10.121

2.  Massive Atenolol, Lisinopril, and Chlorthalidone Overdose Treated with Endoscopic Decontamination, Hemodialysis, Impella Percutaneous Left Ventricular Assist Device, and ECMO.

Authors:  C William Heise; David Beutler; Adam Bosak; Geoffrey Orme; Akil Loli; Kimberlie Graeme
Journal:  J Med Toxicol       Date:  2015-03

3.  Predicative calculation of the efficiency of hemodialysis or hemoperfusion for the removal of drugs from the body.

Authors:  H H Wellhöner
Journal:  Arch Toxicol       Date:  1985-01       Impact factor: 5.153

4.  β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

Authors:  Alvin Tieu; Thomas J Velenosi; Andrew S Kucey; Matthew A Weir; Bradley L Urquhart
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

5.  Dosage adjustment in renal insufficiency.

Authors:  G E Mawer
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

6.  Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis.

Authors:  B L Flouvat; C Imbert; D M Dubois; B P Temperville; A F Roux; G C Chevalier; G Humbert
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

7.  Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.

Authors:  A K Salahudeen; R Wilkinson; J McAinsh; D N Bateman
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

8.  Extracorporeal treatment for poisoning to beta-adrenergic antagonists: systematic review and recommendations from the EXTRIP workgroup.

Authors:  Josée Bouchard; Greene Shepherd; Robert S Hoffman; Sophie Gosselin; Darren M Roberts; Yi Li; Thomas D Nolin; Valéry Lavergne; Marc Ghannoum
Journal:  Crit Care       Date:  2021-06-10       Impact factor: 9.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.